Report #2870591

Received Nov 4, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 74 yrs
State: NC
Recovered: Not recovered
Vaccinated: Jul 9, 2025
Onset: Jul 16, 2025
Days to onset: 7
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	UNK	EH25M	IM

Symptoms (1)

Injection site pain

Symptom narrative

Pain injection site; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in a 74-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number EH25M, expiry date 29-OCT-2025) for prophylaxis. On 09-JUL-2025, the patient received Arexvy (intramuscular, unknown deltoid). On 16-JUL-2025, 7 days after receiving Arexvy, the patient experienced injection site pain (Verbatim: Pain injection site). The outcome of the injection site pain was not resolved. It was unknown if the reporter considered the injection site pain to be related to Arexvy. It was unknown if the company considered the injection site pain to be related to Arexvy. Additional Information: GSK receipt date:16-OCT-2025 The pharmacist reported that a patient received her Arexvy vaccination on 9th July 2025 and about one week later she noted pain about 1 inch below the injection site. The pain continued intermittently.